UNSPSC 41202072: In vitro human immunodeficiency virus (hiv) drug resistance genotype assay

In this classification, this entry connotes a device used to perform an In vitro human immunodeficiency virus (hiv) drug resistance genotype assay. US FDA regulates In vitro human immunodeficiency virus (hiv) drug resistance genotype assay under 21 CFR 866.3090 and under FDA product code NHS.

UNSPSC 41202072 In vitro human immunodeficiency virus (HIV) drug resistance genotype assay is a Commodity code that encompasses rapid HIV screening test kits, HIV/Syphilis reagent supplies for high-volume analyzer platforms, laboratory testing services including specimen collection and confirmation testing, and associated consumables and maintenance services. State and local buyers under this code include state departments of public health and criminal justice, county health services and community supervision agencies, city public health programs, and county health care services. The Illinois Department of Public Health has been a repeat buyer, conducting both emergency sole-source procurements and competitive change orders for Abbott reagents and analyzer supplies; Collin County, Texas appears across multiple health and criminal justice service lines; and the City of Austin has issued consecutive solicitations for rapid HIV test kits through its public health program.

Recent activity spans Illinois, Texas, and Georgia. The Illinois Department of Public Health issued an emergency procurement in May 2026 for Abbott HIV/Syphilis reagents and consumables totaling $38,079.50 and a change order notice in September 2026 (IFB 27482DPHOFCDIB53956, due October 13, 2026) increasing annual testing volume from 15,000 to 25,000 NG/CT tests under a Hologic platform reagent rental agreement, with revised contract cost of $900,000 over five years. Collin County, Texas issued an RFP in September 2026 (2026-327, due July 23, 2026) for offender specimen collection and drug testing services covering approximately 25,031 annual tests at an estimated contract value of $600,000 for two years with three optional one-year renewals, requiring SAMHSA, TX DPS, or CAP lab certification and per-test pricing with screening, confirmation, and alternative testing methodologies. The City of Austin issued consecutive rapid HIV test kit bids—an initial IFB in June 2026 (IFB 9100 AAM1023, due July 17, 2026) and a rebid in August 2026 (IFB 9100 AAM1023REBID, due September 3, 2026)—for Abbott Determine HIV test kits and controls at estimated annual quantities of 375 test kits and 79 control kits, with small business preference available. Gwinnett County, Georgia posted an RFP in September 2026 (PE77023NONST2027000000764, due October 14, 2026) for drug testing supplies compatible with an existing drugs of abuse analyzer, though scope details were not fully specified in available materials.